TY - JOUR
T1 - From revolution to evolution
T2 - The glutamate hypothesis of schizophrenia and its implication for treatment
AU - Moghaddam, Bita
AU - Javitt, Daniel
N1 - Funding Information:
Funded in part by grants R37 (MH48404), R01 (MH084906), Pittsburgh Life Sciences Greenhouse (Bita Moghaddam), and R01DA03383 and P50 MH086385 (Daniel Javitt). This work was supported by National Institute of Mental Health and the Pittsburgh Life Sciences Greenhouse.
PY - 2012/1
Y1 - 2012/1
N2 - Glutamate is the primary excitatory neurotransmitter in mammalian brain. Disturbances in glutamate-mediated neurotransmission have been increasingly documented in a range of neuropsychiatric disorders including schizophrenia, substance abuse, mood disorders, Alzheimer's disease, and autism-spectrum disorders. Glutamatergic theories of schizophrenia are based on the ability of N-methyl-D-aspartate receptor (NMDAR) antagonists to induce schizophrenia-like symptoms, as well as emergent literature documenting disturbances of NMDAR-related gene expression and metabolic pathways in schizophrenia. Research over the past two decades has highlighted promising new targets for drug development based on potential pre-and postsynaptic, and glial mechanisms leading to NMDAR dysfunction. Reduced NMDAR activity on inhibitory neurons leads to disinhibition of glutamate neurons increasing synaptic activity of glutamate, especially in the prefrontal cortex. Based on this mechanism, normalizing excess glutamate levels by metabotropic glutamate group 2/3 receptor agonists has led to potential identification of the first non-monoaminergic target with comparable efficacy as conventional antipsychotic drugs for treating positive and negative symptoms of schizophrenia. In addition, NMDAR has intrinsic modulatory sites that are active targets for drug development, several of which show promise in preclinical/early clinical trials targeting both symptoms and cognition. To date, most studies have been done with orthosteric agonists and/or antagonists at specific sites. However, allosteric modulators, both positive and negative, may offer superior efficacy with less danger of downregulation.
AB - Glutamate is the primary excitatory neurotransmitter in mammalian brain. Disturbances in glutamate-mediated neurotransmission have been increasingly documented in a range of neuropsychiatric disorders including schizophrenia, substance abuse, mood disorders, Alzheimer's disease, and autism-spectrum disorders. Glutamatergic theories of schizophrenia are based on the ability of N-methyl-D-aspartate receptor (NMDAR) antagonists to induce schizophrenia-like symptoms, as well as emergent literature documenting disturbances of NMDAR-related gene expression and metabolic pathways in schizophrenia. Research over the past two decades has highlighted promising new targets for drug development based on potential pre-and postsynaptic, and glial mechanisms leading to NMDAR dysfunction. Reduced NMDAR activity on inhibitory neurons leads to disinhibition of glutamate neurons increasing synaptic activity of glutamate, especially in the prefrontal cortex. Based on this mechanism, normalizing excess glutamate levels by metabotropic glutamate group 2/3 receptor agonists has led to potential identification of the first non-monoaminergic target with comparable efficacy as conventional antipsychotic drugs for treating positive and negative symptoms of schizophrenia. In addition, NMDAR has intrinsic modulatory sites that are active targets for drug development, several of which show promise in preclinical/early clinical trials targeting both symptoms and cognition. To date, most studies have been done with orthosteric agonists and/or antagonists at specific sites. However, allosteric modulators, both positive and negative, may offer superior efficacy with less danger of downregulation.
KW - NMDA receptors
KW - antipsychotic drugs
KW - cognition
KW - dopamine
UR - http://www.scopus.com/inward/record.url?scp=84856120944&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84856120944&partnerID=8YFLogxK
U2 - 10.1038/npp.2011.181
DO - 10.1038/npp.2011.181
M3 - Review article
C2 - 21956446
AN - SCOPUS:84856120944
SN - 0893-133X
VL - 37
SP - 4
EP - 15
JO - Neuropsychopharmacology
JF - Neuropsychopharmacology
IS - 1
ER -